Berry Genomics received National Medical Products Administration Class III approval for PacBio’s Sequel II CNDx system — the first regulatory clearance for a clinical‑grade long‑read sequencer in China — enabling comprehensive detection of SNVs, indels, CNVs, SVs and repeat expansions in a single assay for diagnostics like thalassemia. PacBio highlighted potential gains for complex variant detection and carrier or prenatal testing workflows. Separately, Swiss Rockets secured an exclusive license to MGI/Complete Genomics’ CoolMPS chemistry outside Asia‑Pacific and plans to launch CoolMPS‑based NGS instrumentation next year. Together, these moves indicate growing commercial traction for long‑read and alternative sequencing chemistries as diagnostic-grade genomics expands globally.